Fortress Biotech (FBIO) Fundamentals 2026 — P/E 0.9x, Revenue Analysis | SniperIQ
Fortress Biotech (FBIO) is a US-listed Healthcare company in Biotechnology with a market capitalization of
.54 on the NASDAQ. This SniperIQ fundamentals page covers Fortress Biotech's valuation (P/E 0.9x, P/B 0.7x), profitability (net margin 193.1%), revenue ($63M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Fortress Biotech's market cap?
Fortress Biotech (FBIO) has a market capitalization of approximately
.54 on the NASDAQ. Market cap moves with the live share price.What is Fortress Biotech's P/E ratio?
Fortress Biotech's trailing twelve-month P/E ratio is 0.9x, with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Fortress Biotech?
Fortress Biotech runs a net profit margin of 193.1%, a gross margin of 64.5%, and an operating margin of -84.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Fortress Biotech generate?
Fortress Biotech reported revenue of $63M for fiscal year 2025, with net income of $7M and earnings per share (EPS) of -0.0674. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Fortress Biotech pay a dividend?
Fortress Biotech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Fortress Biotech financially healthy?
Fortress Biotech carries a debt-to-equity ratio of 0.33x and a current ratio of 2.86x, with a market beta of 1.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Fortress Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Fortress Biotech (FBIO) the key facts are: market cap
Track Fortress Biotech's full fundamentals live
Get Fortress Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.